CN1626132A - Medication for treating obstruction of qi in the chest - Google Patents
Medication for treating obstruction of qi in the chest Download PDFInfo
- Publication number
- CN1626132A CN1626132A CN 200310107291 CN200310107291A CN1626132A CN 1626132 A CN1626132 A CN 1626132A CN 200310107291 CN200310107291 CN 200310107291 CN 200310107291 A CN200310107291 A CN 200310107291A CN 1626132 A CN1626132 A CN 1626132A
- Authority
- CN
- China
- Prior art keywords
- adjuvant
- time
- parts
- medicine
- concentrated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 126
- 229940079593 drug Drugs 0.000 title claims description 48
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 282
- 239000000843 powder Substances 0.000 claims description 110
- 239000002671 adjuvant Substances 0.000 claims description 109
- 239000006187 pill Substances 0.000 claims description 105
- 239000000203 mixture Substances 0.000 claims description 85
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 78
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 76
- 235000010447 xylitol Nutrition 0.000 claims description 76
- 239000000811 xylitol Substances 0.000 claims description 76
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 76
- 229960002675 xylitol Drugs 0.000 claims description 76
- 239000007788 liquid Substances 0.000 claims description 69
- 229920002472 Starch Polymers 0.000 claims description 64
- 239000008107 starch Substances 0.000 claims description 64
- 235000019698 starch Nutrition 0.000 claims description 64
- 238000001694 spray drying Methods 0.000 claims description 60
- 239000000758 substrate Substances 0.000 claims description 52
- 241000218628 Ginkgo Species 0.000 claims description 51
- 235000011201 Ginkgo Nutrition 0.000 claims description 51
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 51
- 241000304195 Salvia miltiorrhiza Species 0.000 claims description 50
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims description 50
- 238000003756 stirring Methods 0.000 claims description 47
- 239000003292 glue Substances 0.000 claims description 40
- 238000002156 mixing Methods 0.000 claims description 37
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 36
- 239000008101 lactose Substances 0.000 claims description 35
- 238000002360 preparation method Methods 0.000 claims description 35
- 238000002844 melting Methods 0.000 claims description 31
- 230000008018 melting Effects 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 30
- 238000010438 heat treatment Methods 0.000 claims description 29
- 235000010489 acacia gum Nutrition 0.000 claims description 28
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 28
- 239000002826 coolant Substances 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 238000009413 insulation Methods 0.000 claims description 26
- 229920002545 silicone oil Polymers 0.000 claims description 25
- 241000196324 Embryophyta Species 0.000 claims description 24
- 239000000706 filtrate Substances 0.000 claims description 22
- 210000000115 thoracic cavity Anatomy 0.000 claims description 22
- 238000002481 ethanol extraction Methods 0.000 claims description 21
- 239000000463 material Substances 0.000 claims description 21
- 238000004064 recycling Methods 0.000 claims description 21
- 238000001556 precipitation Methods 0.000 claims description 20
- 238000010992 reflux Methods 0.000 claims description 20
- 239000006228 supernatant Substances 0.000 claims description 20
- 241000233855 Orchidaceae Species 0.000 claims description 19
- 239000000284 extract Substances 0.000 claims description 19
- 210000000689 upper leg Anatomy 0.000 claims description 19
- -1 hydroxypropyl Chemical group 0.000 claims description 14
- 241001597008 Nomeidae Species 0.000 claims description 11
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 10
- 239000000945 filler Substances 0.000 claims description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 229940057995 liquid paraffin Drugs 0.000 claims description 9
- 238000005303 weighing Methods 0.000 claims description 8
- 229920002101 Chitin Polymers 0.000 claims description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 7
- 229920001353 Dextrin Polymers 0.000 claims description 7
- 239000004375 Dextrin Substances 0.000 claims description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 7
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 7
- 235000019425 dextrin Nutrition 0.000 claims description 7
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 7
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 7
- 239000000600 sorbitol Substances 0.000 claims description 7
- 229940032147 starch Drugs 0.000 claims description 7
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 6
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 6
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 6
- 229920000881 Modified starch Polymers 0.000 claims description 6
- 235000010443 alginic acid Nutrition 0.000 claims description 6
- 229920000615 alginic acid Polymers 0.000 claims description 6
- 239000000783 alginic acid Substances 0.000 claims description 6
- 229960001126 alginic acid Drugs 0.000 claims description 6
- 150000004781 alginic acids Chemical class 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 238000002425 crystallisation Methods 0.000 claims description 6
- 230000008025 crystallization Effects 0.000 claims description 6
- 229920001817 Agar Polymers 0.000 claims description 5
- 229920000858 Cyclodextrin Polymers 0.000 claims description 5
- 239000008272 agar Substances 0.000 claims description 5
- 235000010419 agar Nutrition 0.000 claims description 5
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 5
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 5
- 235000010418 carrageenan Nutrition 0.000 claims description 5
- 229920001525 carrageenan Polymers 0.000 claims description 5
- 235000010980 cellulose Nutrition 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 5
- 229920000609 methyl cellulose Polymers 0.000 claims description 5
- 239000001923 methylcellulose Substances 0.000 claims description 5
- 235000010981 methylcellulose Nutrition 0.000 claims description 5
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 5
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 4
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 4
- 229920000591 gum Polymers 0.000 claims description 4
- 239000000905 isomalt Substances 0.000 claims description 4
- 235000010439 isomalt Nutrition 0.000 claims description 4
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 4
- 229920001277 pectin Polymers 0.000 claims description 4
- 239000001814 pectin Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 235000002639 sodium chloride Nutrition 0.000 claims description 4
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 claims description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 4
- 239000008158 vegetable oil Substances 0.000 claims description 4
- 229920001285 xanthan gum Polymers 0.000 claims description 4
- 235000010493 xanthan gum Nutrition 0.000 claims description 4
- 239000000230 xanthan gum Substances 0.000 claims description 4
- 229940082509 xanthan gum Drugs 0.000 claims description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 3
- 244000286663 Ficus elastica Species 0.000 claims description 3
- 240000004584 Tamarindus indica Species 0.000 claims description 3
- 235000004298 Tamarindus indica Nutrition 0.000 claims description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 3
- 239000000679 carrageenan Substances 0.000 claims description 3
- 229940113118 carrageenan Drugs 0.000 claims description 3
- 235000015165 citric acid Nutrition 0.000 claims description 3
- 235000010987 pectin Nutrition 0.000 claims description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 229920000178 Acrylic resin Polymers 0.000 claims description 2
- 239000004925 Acrylic resin Substances 0.000 claims description 2
- 229920000936 Agarose Polymers 0.000 claims description 2
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- 239000004386 Erythritol Substances 0.000 claims description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 239000004368 Modified starch Substances 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 2
- 244000275012 Sesbania cannabina Species 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 2
- 150000005215 alkyl ethers Chemical class 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 235000013877 carbamide Nutrition 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- 238000004132 cross linking Methods 0.000 claims description 2
- 235000019414 erythritol Nutrition 0.000 claims description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 2
- 229940009714 erythritol Drugs 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 235000001727 glucose Nutrition 0.000 claims description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 2
- 239000001341 hydroxy propyl starch Substances 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000013828 hydroxypropyl starch Nutrition 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 235000019426 modified starch Nutrition 0.000 claims description 2
- 229960000292 pectin Drugs 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims description 2
- 229960001947 tripalmitin Drugs 0.000 claims description 2
- 231100000331 toxic Toxicity 0.000 abstract description 7
- 230000002588 toxic effect Effects 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 6
- 230000000694 effects Effects 0.000 description 18
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 15
- 238000012360 testing method Methods 0.000 description 14
- 238000009472 formulation Methods 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 206010061876 Obstruction Diseases 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 238000009833 condensation Methods 0.000 description 9
- 230000005494 condensation Effects 0.000 description 9
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 7
- 229940116229 borneol Drugs 0.000 description 7
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 7
- 208000029078 coronary artery disease Diseases 0.000 description 7
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000000084 colloidal system Substances 0.000 description 6
- 210000000214 mouth Anatomy 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 150000005846 sugar alcohols Polymers 0.000 description 6
- 206010002383 Angina Pectoris Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 210000000038 chest Anatomy 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000000857 drug effect Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 239000006225 natural substrate Substances 0.000 description 4
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 231100000862 numbness Toxicity 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 150000004804 polysaccharides Chemical class 0.000 description 3
- 208000037920 primary disease Diseases 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000035943 smell Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 235000006793 Artemisia stelleriana Nutrition 0.000 description 2
- 244000252230 Artemisia stelleriana Species 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 240000005308 Juniperus chinensis Species 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 235000006413 coastal sagewort Nutrition 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical group C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 241000123611 Dipterocarpaceae Species 0.000 description 1
- 241001411320 Eriogonum inflatum Species 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 244000202052 Poncirus trifoliata Species 0.000 description 1
- 235000000404 Poncirus trifoliata Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000010238 camphora Substances 0.000 description 1
- 229940025250 camphora Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000008563 guizhi decoction Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000001709 ictal effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000003578 releasing effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007560 sedimentation technique Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000026676 system process Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A medicine for treating the obstruction of Qi in the chest is disclosed. Its advantages are high safety and lower toxic by-effect.
Description
Technical field
The present invention relates to field of medicaments, particularly, relating to Chinese medicine is the pharmaceutical preparation of the treatment thoracic obstruction made of raw material.
Background technology
The thoracic obstruction (pained) refers to because of the breast YANG deficiency, YIN-cold, the turbid thorax of crouching that stays of expectorant, or deficiency of heart-QI, agitate weak, due to QI and blood numbness resistance, the heart being lost blood support.Primary disease is the sick class disease of internal organs numbness of main performance with ambition uncomfortable in chest and ictal pain.Primary disease is equivalent to alleged coronary heart disease of modern medicine and ischemic heart desease.Department of Medical Administration of State Administration of Traditional Chinese Medicine thoracic obstruction emergency case cooperative groups is through repeatedly academic discuss, the viewpoint that doctor trained in Western medicine " coronary heart disease " is equivalent to the traditional Chinese medical science " chest-rheumatism " is proposed, and determine to be equivalent to the relevant name of disease of the traditional Chinese medical science according to the Clinical types of coronary heart disease, promptly " angina pectoris " is equivalent to " obstruction of qi in the chest and cardialgia ".
Primary disease is not smooth with heart arteries and veins, and it is main that the breast sun is not declared.It demonstrate,proves many simulataneous insufficiency and excessive, or void is main, or real be main, but that apoplexy due to deficiency is held concurrently more is real, also in fact have void more.In the thoracic obstruction pathological process, can concurrent severe palpitation, disease such as heart failure.The person of being dangerously ill, the big pain in ambition suddenly, and for faint [very] pained.Chinese juniper beach wormwood Bulbus Allii Macrostemonis Chinese liquor soup, Chinese juniper beach wormwood Bulbus Allii Macrostemonis Rhizoma Pinelliae soup, zhishi xiebai guizhi decoction, Ginseng Decoction, Fructus Citri tangerinae trifoliate orange ginger decoction more and more are difficult to adapt to needs of society because of the restriction of its dosage form; And spreaded all over each corner of human lives as modern medicine synthetic chemical substance commonly used, chemical synthetic drug becomes the main flow of medicine, yet, appearance along with multiple difficult serious symptom miscellaneous diseases, western medical treatment presents imperfect, the human lives and the healthy reality and the up-to-date successes achieved in research have all proposed query to this situation, particularly along with the continuous appearance of chemical drugs toxic and side effects, the change of spectrum of disease and conversion of medical, make modern medicine be subjected to unprecedented challenge, and people also place hope in the application and development of traditional medicine on gradually.Advocate back to nature, pay attention to plant amedica use, hanker after traditional remedies, the trend of advocating natural drug forms, making full use of natural materials is human best selections.
At present, in the world, natural drug all has certain market, along with people increasing and the aging of population to the health requirements level of understanding, sub-health stateization, people thirst for back to nature more, the problem of utilize the high Drug therapy of pure natural degree, preventing some chemical synthetic drugs cann't be solved, so the background that exceeds its original traditional national culture has been expanded in the application of natural plant.From natural drug, seek the little and inexpensive medicine of side effect and become the target that countries in the world pharmaceutical manufacturer is chased.The European Community has carried out unified legislation to medical herbs, state medical herbs status such as Canada and Australia have legalized, U.S. government has also drafted the plant amedica management method, the compound recipe mix preparation that begins to accept natural drug is as curative, and these provide good international environment for Chinese medicine enters international medical market as curative.On the other hand, along with the quickening of global economic integration progress, particularly China becomes a full member of WTO, and Chinese Medicine market incorporates the breadth and depth of international medical big market and will further aggravate.Face the enormous impact of Asian countries's traditional medicine product such as the keen competition of powerful transnational medical group and Japan, Korea S, India, Thailand and European countries' plant amedica such as Germany, France, numerous products that China's Chinese medicine produces are owing to still can not meet the standard of international medical market and requirement and being kept outside of the door.
Expansion and human back to nature requirement along with the market global range, use the low medicine of toxic and side effects, especially pure natural medical more and more becomes people's first-selection, dropping pill formulation be a kind of have efficient, quick-acting new medicine preparations, it has overcome the shortcoming and deficiency of Chinese medicine preparation in the past, but present dropping pill formulation generally faces following problem: 1, drop pill adjuvant pure natural degree is not high: at present, drop pill substrate adjuvant mostly is synthetic, natural degree is lower, the searching of new alternative substrate adjuvant, the searching of the alternative substrate adjuvant that particularly natural degree is high and preparation technology thereof determine, it is again very difficult thing, because the required preparation condition of at present common possible natural substrates adjuvant succedaneum is very harsh, it all is to influence the key that drop pill prepares molding that adjuvant temperature and drop pill thereof drip the system condition.The too high then viscosity of adjuvant melt temperature is low, and poor plasticity is though the adjuvant melt temperature is crossed lowplastcity by force, but drop pill has shortcomings such as easily sticking ball, distortion, therefore, seek pure natural degree height, and the adjuvant that is suitable for substituting existing drop pill substrate is a very job of hardships.2, the drop pill outlet encounters problems: along with expanding economy, more and more internationalize in market, China is also just making great efforts to adapt to this trend, present Chinese medicine dripping pills preparation as health food, successful export to many countries, but also face many problems at present, because different countries is different to the approval of the selected adjuvant of Chinese medicine dropping pill formulation, especially industrial flourishing Europe, more strict to food adjuvant and medical auxiliary materials, and as the selected chemosynthesis adjuvant (as Polyethylene Glycol) of the dropping pill formulation of health food outlet not in the catalogue of some national food additive, it is very unfavorable that this moves towards the international market to the Chinese medicine dropping pill formulation, becomes the stumbling-block that Chinese medicine enters the international market, therefore, seek the new of one or more, can be particularly important, also very urgent for the substrate adjuvant that the international market is accepted.3, the shortcoming of mouthfeel and onset speed: the mouthfeel of Chinese medicine and preparation thereof is relatively poor to be the big characteristics of one, people when taking some drugs to the frightened of disagreeable taste that medicine had even be better than fear far away to disease, What is more, some patients are because can not overcome the poor taste of Chinese medicine or its preparation or abnormal smells from the patient and abandon the treatment of Chinese medicine, though can improve mouthfeel as medicine being made capsule or sugar coated tablet, reducing stimulates, but disintegration rate prolongs, be unfavorable for the rapid onset of medicine, to some disease, particularly need the disease of the rapid onset of medicine inapplicable.4, the preparation process difficulty of drop pill suitability for industrialized production: in the replacement process of dropping pill formulation adjuvant, determining of the preparation process of its suitability for industrialized production is very difficult something, as the ratio of the melt temperature of substrate adjuvant, the proportioning of dripping system temperature, adjuvant and medicine, dropper bore, condensing agent etc. all are the factors that influence drop pill, therefore, the replacement of substrate and to be suitable for suitability for industrialized production be a job consuming time, as to expend substantial contribution.
In order to change drop pill substrate adjuvant for a long time based on the situation of chemosynthesis adjuvant, it is low to solve the pure natural degree that present drop pill substrate faced, and can not satisfy more and more that people require back to nature, take low toxicity, the problem of the pure natural medical that has no side effect; Also can solve some problems that Chinese medicine preparation, particularly dropping pill formulation are run in exit procedure, strengthen the competitiveness of international market; The present invention has invented the pure Chinese medicine dripping pills preparation that a kind of toxic and side effects is low, evident in efficacy, moderate, adapt to industrialized great production by a large amount of tests and the research of preparation process.
Summary of the invention
The medicine that the purpose of this invention is to provide a kind of treatment thoracic obstruction with new type natural substrate adjuvant preparation.
Another object of the present invention provides a kind of preparation method for the treatment of thoracic obstruction pharmaceutical preparation.
The present invention is the new pharmacological action that the qi-blood relationship theory learned according to Chinese traditional medicine and modern medicine are found various institutes of Chinese materia medica, according to " symptomatic treatment in acute condition, radical treatment in chronic case; set upright based on reinforcing; " leading to " just must not hinder, " benefit " must not be detained, treating both the principal and secondary aspects of a disease.The medicine of producing according to this method has late result again, and finally reaches the healing purpose the existing short term effect of the treatment of coronary heart disease, and generation without any side effects.The selected substrate adjuvant of the present invention is resulting by a large amount of tests, it is little to have molecular weight, soluble in water, and molten diffusing speed is faster, pure natural degree height, toxic and side effects is lower, and can reduce the medicine irritation abnormal smells from the patient, has the oral cavity of improvement acid-base value during the buccal of oral cavity, improve the characteristics of oral cavity smell, the used substrate adjuvant of the present invention is the agent of food sedan-chair flavor, takes that mouthfeel is good, the acceptant characteristics of patient, is the direction of following substrate adjuvant development.
The consumption of drug component of the present invention and the selection of adjuvant thereof also grope to sum up to draw through the inventor in a large number, each component raw material survival dose and adjuvant thereof all have curative effect preferably in following ranges: 18～55 parts of Folium Ginkgos, 23～68 parts of Salvia miltiorrhiza Bges, 12～36 parts of Herb Gynostemmae Pentaphylli, 2.5～7.5 parts of natural Broneolum Syntheticums, appropriate amount of auxiliary materials is made, wherein adjuvant comprises filler and plasticity substrate, said filler is selected from the natural adjuvant of following one or more plant origins: erythritol, sorbitol, fructose, D-ribonic acid-gamma lactone, arabitol, trehalose, D-ribose, low melting-point agarose, Lac, xylitol, Raffinose, glucose, malic acid, citric acid, isomalt, lactose, maltose etc., and they contain the water of crystallization chemical compound; Said plasticity substrate is selected from the natural adjuvant of following one or more plant origins: starch and derivant thereof, cellulose and derivant thereof, arabic gum, dextran, chitin, sesbania gum, carrageenan, Ficus elastica, Furcellaran, tragakanta, carrageenin, tamarind gum, pectin, xanthan gum, alginic acid and salt thereof, dextrin, cyclodextrin, agar, lactose; Described starch and derivant thereof such as pregelatinized Starch, modified starch, hydroxypropyl starch, carboxymethyl starch, described cellulose and derivant thereof such as methylcellulose, microcrystalline Cellulose, sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, cross-linking sodium carboxymethyl cellulose, hydroxyethylmethyl-cellulose, hydroxyethyl-cellulose, hydroxypropyl cellulose; The consumption of preferred drug component of the present invention and adjuvant thereof are that 30～40 parts of Folium Ginkgos, 35～55 parts of Salvia miltiorrhiza Bges, 20～30 parts of Herb Gynostemmae Pentaphylli, 4～6 parts of natural Broneolum Syntheticums, appropriate amount of auxiliary materials are made, filler adjuvant wherein is selected from following one or more the natural adjuvant of plant origin: sorbitol, xylitol, lactose, maltose, and they contain the water of crystallization chemical compound; Plasticity substrate wherein is selected from following one or more the natural adjuvant of plant origin: pregelatinized Starch, carboxymethyl starch, methylcellulose, sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, arabic gum, alginic acid, dextrin, cyclodextrin, agar, lactose; The consumption of best drug component of the present invention and adjuvant thereof are that 35 parts of Folium Ginkgos, 45 parts of Salvia miltiorrhiza Bges, 25 parts of Herb Gynostemmae Pentaphylli, 5 parts of natural Broneolum Syntheticums, appropriate amount of auxiliary materials are made, and filler adjuvant wherein is selected from following one or more the natural adjuvant of plant origin: xylitol, lactose; Plasticity substrate wherein is selected from following one or more the natural adjuvant of plant origin: starch, arabic gum.
Can also contain chemosynthesis adjuvant and animal origin adjuvant in the above-mentioned dressing, wherein filler comprises phenylglycol, hexadecanol, octadecanol, sodium stearate, tristerin, tripalmitin, carbamide, polyoxyethylene monostearate, polyoxyethylene alkyl ether; Wherein plasticity substrate comprises polyvinylpyrrolidone, crospolyvinylpyrrolidone, carbomer, polyvinyl alcohol, acrylic resin, poloxamer, gelatin.
In screening to above adjuvant, we find: plant colloid such as carrageenan, the tragakanta, pectin, agar, arabic gum, Ficus elastica, tamarind gum, locust bean gum, Pseudobulbus Bletillae (Rhizoma Bletillae) glue, guar gum, Konjac glucomannan, it is big that plant colloids such as POLY-karaya have viscosity, mobile poor, characteristics such as do not solidify after the condensation, and arabic gum has high dense low sticking character, can be mixed with the aqueous solution of 50% concentration and still have flowability, this is one of not available characteristics of other hydrophilic colloid, arabic gum has at high temperature, under the low concentration, can ooze, but not condensation, at low temperature, under the high concentration, be difficult for oozing, but characteristics such as energy condensation.Polysaccharide such as polysaccharide such as starch and derivant thereof (as gelling starch, carboxymethyl starch etc.), cellulose derivative (as methylcellulose, sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose etc.), alginic acid, dextrin, cyclodextrin, lactose, in screening, find alginic acid have viscosity big, be the fruit jelly sample, dextrin has the colloid sample, characteristics such as lactose coagulability difference; And starch and derivant thereof are materials commonly used in the medical science adjuvant, thus in polysaccharide preferred starch and derivant thereof.Polyhydric alcohol such as sorbitol (88～102 ℃), xylitol (88～94.5 ℃), lactose (70～80 ℃), mannitol (166～69 ℃), maltose alcohol (135～140 ℃), isomalt polyhydric alcohol such as (98～103 ℃) screen, and find that it has following characteristics as drop pill substrate: sorbitol, lactose, isomalt are mobile poor; Mannitol, maltose alcohol fusing point are too high; The xylitol coagulability is poor slightly.After Preliminary screening, preferred xylitol, lactose, sorbitol in the selection of polyhydric alcohol, the best is an xylitol.Xylitol has following characteristics as drop pill substrate: in the time of 91 ℃, molten condition has appearred in xylitol, but not fusion fully, cooling rapidly, it separates out crystallization very soon, xylitol mixes the back good fluidity with extractum at certain proportion, can drip and can condensation, but be condensed into Powdered thing, loosely organized, the toughness extreme difference, that pinches is promptly broken.Organic acid and salt, alkali such as citric acid (100 ℃), sorbic acid (133 ℃), succinic acid (181～189 ℃), sodium acetate organic acid such as (58 ℃) and salt, alkali, its as drop pill substrate have fusing point too high, with Chinese medical concrete can't mixing etc. shortcoming.
Because of above single adjuvant existing shortcoming in as the drop pill preparation process, particularly we by above-mentioned Preliminary screening after, determine two kinds of adjuvants are used and screen: mainly be that above various adjuvants are carried out combined sorting, final determine following several: the plant colloid cooperates with the plant colloid, the cooperating of polyhydric alcohol and polyhydric alcohol, polyhydric alcohol and plant colloidally cooperate, the cooperating of the cooperating of xylitol and arabic gum, lactose and arabic gum, based on the composite auxiliary material of xylitol.Find preferred the cooperation to be xylitol, lactose and the compound use of other adjuvant, this kind combination has following characteristics: make up with mannitol: can drip not condensation; Make up with sorbic acid: both do not dissolve each other; Make up with lactose: can drip the energy condensation, but frangible; Make up with pomelo-pectin, tragakanta, sodium alginate: viscosity is big, can't drip; Make up with arabic gum: can drip, coagulability is poor slightly; Make up with dextrin: can drip, coagulability is poor slightly; Make up with starch: can drip, coagulability is also better.Determine that at last best of breed is that xylitol cooperates with arabic gum with starch, xylitol with starch, lactose.
At xylitol and starch, lactose and starch, in the research of xylitol and arabic gum combination, xylitol and starch Application of composite being prepared some required in the process of drop pill factors investigated, mainly is to the xylitol type, condensed fluid, condensate temperature influences the drop pill mouldability, xylitol and starch proportion influence mouldability, temperature is to the influence of drop pill mouldability, the extractum amount influences the drop pill mouldability, mixing time influences the drop pill mouldability, the dropper bore is to the influence of drop pill particle diameter, the formulation optimization of drop pill, the Preliminary Determination of drop pill, dissolve scattered time limit is investigated.Find that the solid xylitol has three types of powder, granular and crystallinity, and the easiest fusion of powder xylitol, again can fine dissolving be dispersed in the mixed liquor that starch, extractum forms, good fluidity, drippage is easy, and granular and crystalline xyhose alcohol is difficult for fusion, solubility property is also slightly poor, the mix flow that they and starch, extractum form is relatively poor, viscosity is very big, almost cannot drip, and therefore drips first-selected powder xylitol in the system process at drop pill.
At ratio of adjuvant molding is found in the sex research, in the combination of xylitol and starch, lactose and starch, xylitol and arabic gum, low melting point substrate adjuvant is 1: 0～1: 1.5 with the ratio of the weight of plasticity substrate adjuvant, be preferably 1: 0.1～1: 0.9, the best is 1: 0.1～1: 0.5.Low melting point substrate adjuvant of being formed within this scope and plasticity substrate adjuvant, the drug matrices fused solution all can ooze, and can condensation.Specific to each combination, xylitol is preferably 1: 0.2 with the ratio of the weight of starch～1: 0.3, and lactose is preferably 1: 0.2 with the ratio of the weight of starch～1: 0.3, and the ratio of the weight of xylitol and arabic gum is preferably 1: 0.2～and 1: 0.4.Find that in the research of temperature temperature is big especially to the influence of drop pill mouldability to the influence of drop pill mouldability, when temperature is too low, owing to the too big effect that oozes that influences drop pill of viscosity of substrate, when temperature is too high, not condensation of drop pill.Find that mixing time can have influence on the mouldability of drop pill in mixing time in to the sex research of drop pill molding, mixing time is too short, and mobile poor, influence oozes, and mixing time is oversize, influences the condensation of drop pill.Dripping under the system temperature, mixing time in 1～120 minute all can, suitable mixing time was at 10～30 minutes.Consider that mixing time can not be too short in the suitability for industrialized production, adopt the method that low temperature stirs for a long time, high temperature drips system.Find that in the research of dropper bore to the influence of drop pill particle diameter the dropper bore influences the size of drop pill and the flowability of fusion substrate, the system effect is dripped in influence.Drop pill diminishes and diminishes along with bore, but after 1.4 millimeters, along with the bore change of size that diminishes is not obvious, but the matrix flow reduction, system is dripped in influence.
So in the preparation method of preparation, medicine mixes mixing time with the substrate adjuvant be 10～30 minutes; The mixed heating and melting temperature of medicine and substrate adjuvant is 45～115 ℃, dripping the system temperature is 45～95 ℃, and liquid coolant is liquid paraffin, methyl-silicone oil or vegetable oil (Oleum Glycines, Semen Ricini wet goods), and the temperature of liquid coolant is-20～25 ℃, dropper mouth internal diameter is 1.0～4.0 millimeters; Preferred heating and melting temperature is 60～85 ℃, and dripping a system temperature is 60～85 ℃, and condensing agent is liquid paraffin, methyl-silicone oil, and the condensing agent temperature is 0～18 ℃, and the dropper bore is 1.1～3.5 millimeters, and the difference of dropper mouth external diameter and internal diameter is less for well; Best heating and melting temperature is that to make temperature be that 64 ℃, dropper bore are that 1.2～2.5 millimeters, condensing agent are 0 ℃ methyl-silicone oil to 64 ℃, droplet.
The substrate adjuvant of the best of the present invention is xylitol and starch, and xylitol is 1: 0.2～1: 0.3 with the ratio of the weight of starch; Or be lactose and starch, lactose is 1: 0.2～1: 0.3 with the ratio of the weight of starch; Or be xylitol and arabic gum, the ratio of the weight of xylitol and arabic gum is 1: 0.2～1: 0.4.
Xylitol is-kind of natural plant sweetening agent, approve through World Health Organization (WHO), xylitol is a kind of safest sweeting agent, countries in the world are extensive use of in fields such as food and oral-cavity articles, xylitol enters the help that need not insulin in the cell, when sugar utilizes obstacle, can not cause blood sugar increasing yet, can improve diabetics symptom, have the ketoplastic effect of powerful inhibition, can promote the generation of liver glycogen, directly infiltrate the Developmental and Metabolic Disorder that tissue is participated in metabolism, can be corrected protein, fat and steroid; Xylose is the internal metabolism intermediate product, and body has higher toleration to it.Clinical practice proves: the highest oral dosis tolerata can reach 220g every day, and intravenous drip every day can reach 100g.The oral 25700mg/Kg of median lethal dose(LD 50) (LD50) mice, quiet notes 6400mg/Kg, the quiet notes of rat 6200mg/Kg.
Medicine mesostroma adjuvant of the present invention and amount of drug are than can being the scope that allows on the galenic pharmacy, medicine described here can be that crude drug also can be the effective ingredient extract, in order to adapt to industrialized great production, the ratio range of mesostroma adjuvant of the present invention and medicine refers to the weight proportion of adjuvant and extract drugs extractum, and the substrate adjuvant is 1: 0.1～1: 1 with the ratio of the weight of drug extract; Preferred substrate adjuvant is 1: 0.1～1: 0.6 with the ratio of the weight of extract drugs extractum; Best substrate adjuvant is 1: 0.2～1: 0.4 with the ratio of the extraction extractum weight of medicine.
Medicine of the present invention can adopt the preparation of Chinese medicine preparation conventional method.The preparation of effective ingredient of the present invention can be adopted following method: water extraction, decoction and alcohol sedimentation technique, extraction, infusion process, percolation, reflux extraction, continuous backflow extraction method, macroreticular resin absorbing method preparation.For example, these crude drug pulverize mix homogeneously can be made powder takes after mixing it with water; Also can be with these medicines decocting together, the condensed water decocting liquid is made oral liquid then; But, preferably adopt following technology to extract, but this can not limit protection scope of the present invention to raw material in order to make each crude drug of this medicine better bring into play drug effect.
The preparation method of medicine of the present invention is as follows:
(a) it is standby to take by weighing 18～55 parts of each crude drug Folium Ginkgos, 23～68 parts of Salvia miltiorrhiza Bges, 12～36 parts of Herb Gynostemmae Pentaphylli, 2.5～7.5 parts of natural Broneolum Syntheticums by proportioning;
(b) Folium Ginkgo is with 50～90% ethanol extraction secondary, each 0.5～5 hour, filter, consider liquid and reclaim ethanol, be concentrated into relative density and be 1.05～1.35 clear paste, spray drying, dried powder; Salvia miltiorrhiza Bge decocts with water three times, 1～5 hour for the first time; 0.5～4 hour for the second time, 0.5～2 hour for the third time, filter, merge and consider liquid, be concentrated into the clear paste of relative density 1.10～1.35, add ethanol and make that to contain alcohol amount be 50～85%, stirring makes precipitation, gets supernatant and reclaims ethanol, is concentrated into relative density and is 1.10～1.35 clear paste, spray drying, it is standby to get dry fine powder; Glue thigh orchid is with 50～95% alcohol reflux secondary, and each 0.5～5 hour, filter, filtrate recycling ethanol is concentrated in the time of 10～40 ℃ relative density and is 1.05～1.35 clear paste spray drying and gets dried powder;
(c) natural Broneolum Syntheticum is ground into fine powder, with above-mentioned powder mixes, add in the appropriate amount of auxiliary materials, fully mix, mixture is at 45～115 ℃ of heating and meltings, stir, mixing time is 1～120 minute, insulation, at 45～95 ℃ of temperature following system, dropper bore is 1.0～4.0 millimeters, splash in-20～25 ℃ liquid paraffin, methyl-silicone oil or the vegetable oil, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Preferred manufacturing procedure comprises the following steps:
(a) it is standby to take by weighing 30～40 parts of each crude drug Folium Ginkgos, 35～55 parts of Salvia miltiorrhiza Bges, 20～30 parts of Herb Gynostemmae Pentaphylli, 4～6 parts of natural Broneolum Syntheticums by proportioning;
(b) Folium Ginkgo is with 60～80% ethanol extraction secondary, each 1～3 hour, filter, consider liquid and reclaim ethanol, be concentrated into relative density and be 1.15～1.30 clear paste, spray drying, dried powder; Salvia miltiorrhiza Bge decocts with water three times, 2～4 hours for the first time; 1～3 hour for the second time, 0.5～1.5 hour for the third time, filter, merge and consider liquid, be concentrated into the clear paste of relative density 1.15～1.30, add ethanol and make that to contain alcohol amount be 60～80%, stirring makes precipitation, gets supernatant and reclaims ethanol, is concentrated into relative density and is 1.15～1.30 clear paste, spray drying, it is standby to get dry fine powder; Glue thigh orchid is with 60～80% alcohol reflux secondary, and each 1～3 hour, filter, filtrate recycling ethanol is concentrated in the time of 15～30 ℃ relative density and is 1.15～1.30 clear paste spray drying and gets dried powder;
(c) natural Broneolum Syntheticum is ground into fine powder, with above-mentioned powder mixes, add in the appropriate amount of auxiliary materials, fully mix, mixture is at 60～85 ℃ of heating and meltings, stir, mixing time is 10～30 minutes, insulation, at 60～85 ℃ of temperature following system, dropper bore is 1.1～3.5 millimeters, splash in 0～18 ℃ the liquid paraffin, methyl-silicone oil, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Best preparation method comprises the following steps:
(a) it is standby to take by weighing 35 parts of each crude drug Folium Ginkgos, 45 parts of Salvia miltiorrhiza Bges, 25 parts of Herb Gynostemmae Pentaphylli, 5 parts of natural Broneolum Syntheticums by proportioning;
(b) Folium Ginkgo is with 70% ethanol extraction secondary, each 2 hours, filter, consider liquid and reclaim ethanol, be concentrated in the time of 20 ℃ relative density and be 1.20～1.25 clear paste, spray drying, dried powder; Salvia miltiorrhiza Bge decocts with water three times, 3 hours for the first time; 2 hours for the second time, 1 hour for the third time, filter, merge and consider liquid, be concentrated into the clear paste of relative density 1.20 in the time of 40 ℃, add ethanol and make that to contain alcohol amount be 75%, stirring makes precipitation, gets supernatant and reclaims ethanol, is concentrated in the time of 20 ℃ relative density and is 1.20～1.25 clear paste, spray drying, it is standby to get dry fine powder; Glue thigh orchid is with 75% alcohol reflux secondary, each 2 hours, filter, filtrate recycling ethanol is concentrated in the time of 20 ℃ relative density and is 1.20～1.25 clear paste spray drying, dried powder;
(c) natural Broneolum Syntheticum is ground into fine powder, with above-mentioned powder mixes, add in the appropriate amount of auxiliary materials, fully mix, mixture is at 64 ℃ of heating and meltings, stir, mixing time is 10～30 minutes, insulation, at 64 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splash in 0 ℃ the methyl-silicone oil, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
The best preparation method of medicine of the present invention is:
(a) it is standby to take by weighing 35 parts of each crude drug Folium Ginkgos, 45 parts of Salvia miltiorrhiza Bges, 25 parts of Herb Gynostemmae Pentaphylli, 5 parts of natural Broneolum Syntheticums by proportioning;
(b) Folium Ginkgo is with 70% ethanol extraction secondary, each 2 hours, filter, consider liquid and reclaim ethanol, be concentrated in the time of 20 ℃ relative density and be 1.20～1.25 clear paste, spray drying, dried powder; Salvia miltiorrhiza Bge decocts with water three times, 3 hours for the first time; 2 hours for the second time, 1 hour for the third time, filter, merge and consider liquid, be concentrated into the clear paste of relative density 1.20 in the time of 40 ℃, add ethanol and make that to contain alcohol amount be 75%, stirring makes precipitation, gets supernatant and reclaims ethanol, is concentrated in the time of 20 ℃ relative density and is 1.20～1.25 clear paste, spray drying, it is standby to get dry fine powder; Glue thigh orchid is with 75% alcohol reflux secondary, each 2 hours, filter, filtrate recycling ethanol is concentrated in the time of 20 ℃ relative density and is 1.20～1.25 clear paste spray drying, dried powder;
(c) natural Broneolum Syntheticum is ground into fine powder, with above-mentioned powder mixes, adds an amount of xylitol and starch, xylitol is 1: 0.2～1: 0.3 with the ratio of the weight of starch; Or adding lactose and starch, lactose is 1: 0.2～1: 0.3 with the ratio of the weight of starch; Or adding xylitol and arabic gum, the ratio of the weight of xylitol and arabic gum is in 1: 0.2～1: 0.4 the adjuvant, fully mix, mixture stirs at 64 ℃ of heating and meltings, mixing time is 10～30 minutes, insulation is 1.2～2.5 millimeters at 64 ℃ of temperature following system, dropper bore, splashes in 0 ℃ the methyl-silicone oil, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
More than form when producing and to increase or to reduce according to corresponding ratio, as large-scale production can be unit with kilogram or with the ton, small-scale production can be unit with the gram also, and weight can increase or reduce, but the crude drug material weight proportion constant rate between each composition.
More than each single medicinal material in forming, especially adjuvant drug, messenger drug or adjuvant drug and messenger drug, can be replaced by suitable Chinese medicine individually or simultaneously with the identical property of medicine, effect, it is constant to replace back Chinese medicine preparation and drug effect thereof, Borneolum Syntheticum can change the succedaneum of Blumeae preparatum Tabellae and Borneolum Syntheticum in the present invention, but the present invention is influenced not quite.Borneolum Syntheticum is the processed goods of Dipterocarpaceae short, bristly hair or beard thing Borneolum Syntheticum resin, or is Camphora, the synthetic product of being processed into of Lignum Pini Nodi wet goods chemical method.The former is distributed in the South Sea Islands one band, and the latter is originated in ground such as Shanghai, Beijing, Guangzhou, Tianjin.Other has the crystallization from the leaf extraction of Compositae short, bristly hair or beard thing Herba Blumeae Balsamiferae, practises claiming " Blumeae preparatum Tabellae " (left-handed Borneolum Syntheticum).The another name of Borneolum Syntheticum is borneolum syntheticum, Borneolum Syntheticum, borneol, Blumeae preparatum Tabellae again.
Medicine of the present invention can be determined usage and dosage according to patient's situation in use, but every day 1-3 time, and every day, each crude drug consumption was as the criterion with the state-promulgated pharmacopoeia dosage, was no more than the pharmacopeia ormal weight.
The drop pill that the present invention is prepared, conventional drop pill advantage is simple as preparing except having, steady quality, can make liquid medicine solidification, convenient drug administration, efficient, quick-acting, its biggest advantage is:
1, the selected adjuvant pure natural of the present invention degree height: the substrate adjuvant that employed substrate adjuvant derives from natural plants or originates based on natural plants among the present invention, selected substrate adjuvant is xylitol and starch or lactose and starch or xylitol and arabic gum, this substrate adjuvant has pure natural degree height, toxic and side effects is low, mouthfeel is good, dissolve scattered time limit is short, rapid-action, it is a kind of new medium adjuvant, can be used for substituting present chemosynthesis adjuvant, the drop pill made from this kind adjuvant, it is low to solve the pure natural degree that present drop pill substrate faced, and more and more can not satisfy people and require back to nature, take low toxicity, the problem of the pure natural medical that has no side effect.
2, some problems in the outlet of solution Chinese medicine: medicine of the present invention also can solve Chinese medicine preparation, some problems of in exit procedure, being run into of dropping pill formulation particularly, solve because different countries, especially the European countries of industry prosperity are to the difference identification of the selected adjuvant of Chinese medicine dropping pill formulation, overcome as the selected adjuvant Polyethylene Glycol of the dropping pill formulation of the health food outlet defective in some national food additive catalogue not, improve the Chinese medicine dripping pills preparation and move towards the international market, strengthen the competitiveness of international market.
3, solve the relatively poor problem of drop pill taste and further improve drug effect speed (dissolve scattered time limit): the medicinal dropping ball made from this kind substrate adjuvant of the present invention, can improve Chinese medicine preparation, the particularly present not good shortcoming of dropping pill formulation taste, improve mouthfeel, more easy for patients to accept, and the drop pill that adopts the selected adjuvant of medicine of the present invention to make has shorter dissolve scattered time limit, making drug effect faster, is the medicine that the thoracic obstruction is treated in a kind of onset faster.
4, higher safety and solve some problems in the drop pill storage process: the selected substrate of the present invention is not only additive, nutrient commonly used in the food industry, and can do medicinal, but do not see that it uses as the drug matrices adjuvant, therefore, with regard to substrate, be perfectly safe, have no side effect, a large amount of evidences, the drop pill made from this adjuvant can reduce effective ingredient separating out in storage process, the sticking ball of drop pill, easy shortcomings such as moisture absorption deliquescing, but the big production of suitability for industrialized.
The present invention is under instruction of Chinese Medicine theory, preparation technology's test that process is a large amount of and pharmacology, the resulting preparation of pharmacodynamics test.The present invention is evident in efficacy, has blood circulation promoting and blood stasis dispelling, the effect of coronary circulation-promoting pain-relieving, be used for the treatment of obstruction of qi in the chest and cardialgia clinically,, be applicable to coronary heart disease, angina pectoris that the resistance of treatment blood stasis numbness causes as diseases such as treatment coronary heart disease, angina pectoris, myocardial ischemia, uncomfortable in chest, chest pain that disease is seen, cardiopalmus, symptom such as breathe hard.Reasonable recipe of the present invention, poisonous side effect of medicine is low, has overcome that western medicine coronary heart disease toxic and side effects is big, expense is high, and the Chinese medicine curative effect is low, flavour of a drug are many, the shortcoming of incompatibility large-scale production, is the medicine of the definite treatment thoracic obstruction of a kind of economy, material benefit, curative effect.
In order to understand the present invention better, dissolve scattered time limit, weight differential, drop pill soft durometer, the drop pill with YINDAN XINTAI DIWAN glues test explanation advantages of the present invention such as ball below.
Test example 1: dissolve scattered time limit, weight differential contrast experiment's example
In vitro tests
The present invention be that the YINDAN XINTAI DIWAN that adjuvant is made compares with the Polyethylene Glycol, by measuring dissolve scattered time limit, investigate its good releasing effect; By measuring indexs such as the ball method of double differences is different, whether ripe, whether be fit to suitability for industrialized production if investigating its preparation technology.
1. test medication: the new substrate YINDAN XINTAI DIWAN of the present invention (newly), Tianjin Tasly Pharmaceutical Co., Ltd provides, and is the YINDAN XINTAI DIWAN (old) that adjuvant is made with the Polyethylene Glycol, and Guizhou Junzhitang Pharmaceutical Co., Ltd. produces.
2. method and result:
Dissolve scattered time limit: by " method is measured under this item of Chinese pharmacopoeia; The ball method of double differences is different: by " method is measured under this item of Chinese pharmacopoeia.Result of the test sees Table 1.
Three batches of YINDAN XINTAI DIWAN made from the new medium adjuvant of table 1 (newly) with the polyethylene glycol 6000 be YINDAN XINTAI DIWAN (old) dissolve scattered time limit made of adjuvant, weight differential relatively
| 0 month | January | February | March | June | December | 18 months | ||
| 1 batch | Criterion | The result | ||||||
| Weight differential (± 15%) | All in 10% | All in 10% | All in 10% | All in 10% | All in 10% | All in 10% | All in 10% | |
| Dissolve scattered time limit (newly) (30 minutes) (old) | ??2′1″ ????5′10″ | ??2′1″ ????5′16″ | ??2′5″ ????5′11″ | ??2′7″ ????5′14″ | ??2′8″ ????5′13″ | ??2′10″ ????5′12″ | ??2′12″ ????5′15″ | |
| 2 batches | Weight differential (± 15%) | All in 10% | All in 10% | All in 10% | All in 10% | All in 10% | All in 10% | All in 10% |
| Dissolve scattered time limit (newly) (30 minutes) (old) | ??2′0″ ????5′10″ | ??2′1″ ????5′10″ | ??2′4″ ????5′11″ | ??2′5″ ????5′11″ | ??2′9″ ????5′12″ | ??2′11″ ????5′14″ | ??2′11″ ????5′13″ | |
| 3 batches | Weight differential (± 15%) | All in 10% | All in 10% | All in 10% | All in 10% | All in 10% | All in 10% | All in 10% |
| Dissolve scattered time limit (newly) (30 minutes) (old) | ??2′1″ ????5′10″ | ??2′2″ ????5′11″ | ??2′5″ ????5′13″ | ??2′6″ ????5′18″ | ??2′7″ ????5′16″ | ??2′9″ ????5′0″ | ??2′13″ ????5′13″ | |
Test data shows, the dissolve scattered time limit of new substrate YINDAN XINTAI DIWAN is lacking of the YINDAN XINTAI DIWAN made of adjuvant with the Polyethylene Glycol; Newly, the ball method of double differences of the YINDAN XINTAI DIWAN made of old substrate is different all in the pharmacopeia prescribed limit.Result of the test explanation, the molten diffusing speed of the YINDAN XINTAI DIWAN made from novel adjuvant is faster, is more conducive to medicine and plays a role in the shortest time; The ball method of double differences is different all to be controlled in the pharmacopeia prescribed limit, and the alternative present chemosynthesis adjuvant of this natural substrates adjuvant is described, but suitability for industrialized production.
Test example 2: the present invention with the polyethylene glycol 6000 be the sticking ball comparative observation of YINDAN XINTAI DIWAN soft durometer, drop pill that adjuvant is made
1. test medication: the new substrate YINDAN XINTAI DIWAN of the present invention (newly) is the YINDAN XINTAI DIWAN (old) that adjuvant is made with the Polyethylene Glycol.
2. method and result: three batches of the things of getting it filled are loaded in the porcelain vase respectively, and use the bottle stopper good seal.Putting it into the bottom has in the exsiccator of saturated Nacl (humidity 75%) solution, exsiccator is put into 40 ℃ of drying baker of constant temperature again, and timing sampling is observed situations such as drop pill soft durometer, the sticking ball of drop pill, the results are shown in Table 2.1, table 2.2.
Three batches in table 2.1 is that the YINDAN XINTAI DIWAN reserved sample observing that adjuvant is made compares with the polyethylene glycol 6000
| 0 month | January | February | March | June | December | 18 months | ||
| 1 batch | Criterion | The result | ||||||
| Sticking ball | Not sticking | Not sticking | Not sticking | Not sticking | Not sticking | Sticking slightly | Sticking slightly | |
| Soft durometer | Firmly | Firmly | Firmly | Firmly | Firmly | Harder | Harder | |
| 2 batches | Sticking ball | Not sticking | Not sticking | Not sticking | Not sticking | Not sticking | Not sticking | Sticking slightly |
| Soft durometer | Firmly | Firmly | Firmly | Firmly | Firmly | Harder | Harder | |
| 3 batches | Sticking ball | Not sticking | Not sticking | Not sticking | Not sticking | Not sticking | Sticking slightly | Sticking slightly |
| Soft durometer | Firmly | Firmly | Firmly | Firmly | Firmly | Harder | Harder | |
Table 2.2: three batches of YINDAN XINTAI DIWAN made from the new medium adjuvant (newly) with the polyethylene glycol 6000 be YINDAN XINTAI DIWAN (old) character observation made of adjuvant relatively
| 0 month | January | February | March | June | December | 18 months | ||
| Criterion | The result | |||||||
| 1 batch | Sticking ball | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) slightly | Sticking (old) glues (newly) slightly slightly | Sticking (old) be sticking (newly) slightly |
| Soft durometer | (old) hard (newly) firmly | (old) hard (newly) firmly | (old) hard (newly) firmly | (old) hard (newly) firmly | Hard (old) hard (newly) | Hard slightly (old) hard (newly) | Hard slightly (old) be hard (newly) slightly | |
| 2 batches | Sticking ball | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) slightly | Sticking (old) glues (newly) slightly slightly |
| Soft durometer | (old) hard (newly) firmly | (old) hard (newly) firmly | (old) hard (newly) firmly | (old) hard (newly) firmly | Hard (old) hard (newly) | Hard slightly (old) hard (newly) | Hard slightly (old) be hard (newly) slightly | |
| 3 batches | Sticking ball | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) slightly | Sticking (old) do not glue (newly) slightly | Sticking (old) be sticking (newly) slightly |
| Soft durometer | (old) hard (newly) firmly | (old) hard (newly) firmly | (old) hard (newly) firmly | (old) hard (newly) firmly | (old) hard (newly) firmly | Hard slightly (old) hard (newly) | Hard slightly (old) be hard (newly) slightly | |
Test data shows, the soft durometer of new substrate YINDAN XINTAI DIWAN changes and be that the YINDAN XINTAI DIWAN made of adjuvant is similar, strong slightly with the Polyethylene Glycol; Sticking ball variation, the firmness change of new substrate YINDAN XINTAI DIWAN and be that the YINDAN XINTAI DIWAN made of adjuvant is similar with the Polyethylene Glycol.Presentation of results, the sticking ball of the YINDAN XINTAI DIWAN that new, old substrate adjuvant is made changes, firmness change is similar, and the alternative present chemosynthesis adjuvant of this natural substrates adjuvant is described, but suitability for industrialized production.
The specific embodiment
Embodiment 1
(a) get Folium Ginkgo 18g, Salvia miltiorrhiza Bge 23g, Herb Gynostemmae Pentaphylli 12g, natural Broneolum Syntheticum 2.5g, xylitol 22.5g, starch 4.5g are standby;
(b) Folium Ginkgo is with 50～90% ethanol extraction secondary, each 5 hours, filter, consider liquid and reclaim ethanol, be concentrated into relative density and be 1.25～1.35 clear paste, spray drying, dried powder; Salvia miltiorrhiza Bge decocts with water three times, 5 hours for the first time; 4 hours for the second time, 2 hours for the third time, filter, merge and consider liquid, be concentrated into the clear paste of relative density 1.20～1.35, add ethanol and make that to contain alcohol amount be 50～85%, stirring makes precipitation, gets supernatant and reclaims ethanol, is concentrated into relative density and is 1.20～1.35 clear paste, spray drying, it is standby to get dry fine powder; Glue thigh orchid is with 50～95% alcohol reflux secondary, and each 5 hours, filter, filtrate recycling ethanol is concentrated in the time of 30～40 ℃ relative density and is 1.25～1.35 clear paste spray drying and gets dried powder;
(c) natural Broneolum Syntheticum is ground into fine powder,, adds in xylitol and the starch mixture with above-mentioned powder mixes, fully mix, mixture stirs at 45～115 ℃ of heating and meltings, and mixing time is 15 minutes, insulation, at 45～95 ℃ of temperature following system, dropper bore is 1.0～4.0 millimeters, splashes in-20～25 ℃ the methyl-silicone oil, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 2
(a) get Folium Ginkgo 55g, Salvia miltiorrhiza Bge 30g, Herb Gynostemmae Pentaphylli 36g, natural Broneolum Syntheticum 5.5g, lactose 20g, starch 5g are standby;
(b) Folium Ginkgo is with 80～90% ethanol extraction secondary, each 4 hours, filter, consider liquid and reclaim ethanol, be concentrated into relative density and be 1.15～1.25 clear paste, spray drying, dried powder; Salvia miltiorrhiza Bge decocts with water three times, 4 hours for the first time; 3 hours for the second time, 1 hour for the third time, filter, merge and consider liquid, be concentrated into the clear paste of relative density 1.10～1.25, add ethanol and make that to contain alcohol amount be 50～55%, stirring makes precipitation, gets supernatant and reclaims ethanol, is concentrated into relative density and is 1.10～1.25 clear paste, spray drying, it is standby to get dry fine powder; Glue thigh orchid is with 80～95% alcohol reflux secondary, and each 3 hours, filter, filtrate recycling ethanol is concentrated in the time of 10～20 ℃ relative density and is 1.15～1.25 clear paste spray drying and gets dried powder;
(c) natural Broneolum Syntheticum is ground into fine powder,, adds in lactose and the starch mixture with above-mentioned powder mixes, fully mix, mixture stirs at 95～115 ℃ of heating and meltings, and mixing time is 10～20 minutes, insulation, at 45～75 ℃ of temperature following system, dropper bore is 1.20～4.0 millimeters, splashes in-20～25 ℃ the vegetable oil, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 3
(a) get Folium Ginkgo 18g, Salvia miltiorrhiza Bge 68g, Herb Gynostemmae Pentaphylli 30g, natural Broneolum Syntheticum 2.5g, xylitol 20.7g, arabic gum 6.3g are standby;
(b) Folium Ginkgo is with 70% ethanol extraction secondary, each 2 hours, filter, consider liquid and reclaim ethanol, the concentrated solution spray drying, dried powder; Salvia miltiorrhiza Bge decocts with water three times, 3 hours for the first time; 2 hours for the second time, 1 hour for the third time, filter, merge and consider liquid, be concentrated into the clear paste of relative density 1.10～1.35, add ethanol and make that to contain the alcohol amount be 80～85%, stir and make precipitation, get supernatant and reclaim ethanol, the concentrated solution spray drying, dry fine powder is standby; Glue thigh orchid is with 75% alcohol reflux secondary, and each 0.5～5 hour, filter, filtrate recycling ethanol is concentrated in the time of 10～40 ℃ relative density and is 1.05～1.35 clear paste spray drying and gets dried powder;
(c) natural Broneolum Syntheticum is ground into fine powder,, adds in xylitol and the arabic gum mixture with above-mentioned powder mixes, fully mix, mixture stirs at 55～75 ℃ of heating and meltings, and mixing time is 20 minutes, insulation, at 55～75 ℃ of temperature following system, dropper bore is 1.50～4.0 millimeters, splashes in 0～10 ℃ the liquid paraffin, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 4
(a) get Folium Ginkgo 20g, Salvia miltiorrhiza Bge 25g, Herb Gynostemmae Pentaphylli 15g, natural Broneolum Syntheticum 3g, xylitol 26.5g, xanthan gum 3.5g are standby;
(b) Folium Ginkgo is with 70% ethanol extraction secondary, each 2 hours, filter, consider liquid and reclaim ethanol, be concentrated into relative density and be 1.05～1.15 clear paste, spray drying, dried powder; Salvia miltiorrhiza Bge decocts with water three times, 3 hours for the first time; 2 hours for the second time, 1 hour for the third time, filter, merge and consider liquid, be concentrated into the clear paste of relative density 1.10～1.15, add ethanol and make that to contain alcohol amount be 50～65%, stirring makes precipitation, gets supernatant and reclaims ethanol, is concentrated into relative density and is 1.10～1.15 clear paste, spray drying, it is standby to get dry fine powder; Glue thigh orchid is with 50～95% alcohol reflux secondary, and each 2 hours, filter, filtrate recycling ethanol is concentrated in the time of 10～40 ℃ relative density and is 1.15～1.25 clear paste spray drying and gets dried powder;
(c) natural Broneolum Syntheticum is ground into fine powder,, adds in xylitol and the xanthan gum mixtures with above-mentioned powder mixes, fully mix, mixture stirs at 45～75 ℃ of heating and meltings, and mixing time is 30 minutes, insulation, at 45～65 ℃ of temperature following system, dropper bore is 1.30～3.0 millimeters, splashes in 5～15 ℃ the liquid paraffin, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 5
(a) get Folium Ginkgo 35g, Salvia miltiorrhiza Bge 45g, Herb Gynostemmae Pentaphylli 25g, natural Broneolum Syntheticum 5g, xylitol 17.5g, starch 3.5g are standby;
(b) Folium Ginkgo is with 70% ethanol extraction secondary, each 2 hours, filter, consider liquid and reclaim ethanol, be concentrated in the time of 20 ℃ relative density and be 1.20～1.25 clear paste, spray drying, dried powder; Salvia miltiorrhiza Bge decocts with water three times, 3 hours for the first time; 2 hours for the second time, 1 hour for the third time, filter, merge and consider liquid, be concentrated into the clear paste of relative density 1.20 in the time of 40 ℃, add ethanol and make that to contain alcohol amount be 75%, stirring makes precipitation, gets supernatant and reclaims ethanol, is concentrated in the time of 20 ℃ relative density and is 1.20～1.25 clear paste, spray drying, it is standby to get dry fine powder; Glue thigh orchid is with 75% alcohol reflux secondary, each 2 hours, filter, filtrate recycling ethanol is concentrated in the time of 20 ℃ relative density and is 1.20～1.25 clear paste spray drying, dried powder;
(c) natural Broneolum Syntheticum is ground into fine powder,, adds in xylitol and the starch mixture with above-mentioned powder mixes, fully mix, mixture stirs at 64 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 64 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splashes in 0 ℃ the methyl-silicone oil, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 6
(a) by proportioning take by weighing each crude drug Folium Ginkgo 35g, Salvia miltiorrhiza Bge 45g, Herb Gynostemmae Pentaphylli 25g, Blumeae preparatum Tabellae 5g, lactose 15g, starch 6g are standby;
(b) Folium Ginkgo is with 70% ethanol extraction secondary, each 2 hours, filter, consider liquid and reclaim ethanol, be concentrated in the time of 20 ℃ relative density and be 1.20～1.25 clear paste, spray drying, dried powder; Salvia miltiorrhiza Bge decocts with water three times, 3 hours for the first time; 2 hours for the second time, 1 hour for the third time, filter, merge and consider liquid, be concentrated into the clear paste of relative density 1.20 in the time of 40 ℃, add ethanol and make that to contain alcohol amount be 75%, stirring makes precipitation, gets supernatant and reclaims ethanol, is concentrated in the time of 20 ℃ relative density and is 1.20～1.25 clear paste, spray drying, it is standby to get dry fine powder; Glue thigh orchid is with 75% alcohol reflux secondary, each 2 hours, filter, filtrate recycling ethanol is concentrated in the time of 20 ℃ relative density and is 1.20～1.25 clear paste spray drying, dried powder;
(c) Blumeae preparatum Tabellae is ground into fine powder, with above-mentioned powder mixes, add in lactose and the starch mixture, fully mix, mixture is at 64 ℃ of heating and meltings, stir, mixing time is 10～30 minutes, insulation, at 64 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splash in 0 ℃ the methyl-silicone oil, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 7
(a) get Folium Ginkgo 40g, Salvia miltiorrhiza Bge 55g, Herb Gynostemmae Pentaphylli 20g, natural Broneolum Syntheticum 4g, xylitol 16.5g, starch 5.5g are standby;
(b) Folium Ginkgo is with 60～80% ethanol extraction secondary, each 3.5 hours, filter, consider liquid and reclaim ethanol, be concentrated into relative density and be 1.15～1.30 clear paste, spray drying, dried powder; Salvia miltiorrhiza Bge decocts with water three times, 3 hours for the first time; 2 hours for the second time, 1 hour for the third time, filter, merge and consider liquid, be concentrated into the clear paste of relative density 1.15～1.30, add ethanol and make that to contain alcohol amount be 60～80%, stirring makes precipitation, gets supernatant and reclaims ethanol, is concentrated into relative density and is 1.15～1.30 clear paste, spray drying, it is standby to get dry fine powder; Glue thigh orchid is with 60～80% alcohol reflux secondary, and each 3 hours, filter, filtrate recycling ethanol is concentrated in the time of 15～30 ℃ relative density and is 1.15～1.30 clear paste spray drying and gets dried powder;
(c) natural Broneolum Syntheticum is ground into fine powder, with above-mentioned powder mixes, add in xylitol and the starch mixture, fully mix, mixture is at 60～85 ℃ of heating and meltings, stir, mixing time is 10～30 minutes, insulation, at 60～85 ℃ of temperature following system, dropper bore is 1.1～3.5 millimeters, splash in 0～18 ℃ the methyl-silicone oil, make 1000 to the greatest extent and wipe liquid coolant, promptly the drop pill drop.
Embodiment 8
(a) get Folium Ginkgo 30g, Salvia miltiorrhiza Bge 35g, Herb Gynostemmae Pentaphylli 20g, natural Broneolum Syntheticum 4g, xylitol 25.5g, Furcellaran 5.5g are standby;
(b) Folium Ginkgo is with 80% ethanol extraction secondary, each 2 hours, filter, consider liquid and reclaim ethanol, be concentrated into relative density and be 1.15～1.30 clear paste, spray drying, dried powder; Salvia miltiorrhiza Bge decocts with water three times, 3.5 hours for the first time; 2 hours for the second time, 1 hour for the third time, filter, merge and consider liquid, be concentrated into the clear paste of relative density 1.15～1.30, add ethanol and make that to contain alcohol amount be 60～80%, stirring makes precipitation, gets supernatant and reclaims ethanol, is concentrated into relative density and is 1.15～1.30 clear paste, spray drying, it is standby to get dry fine powder; Glue thigh orchid is with 80% alcohol reflux secondary, and each 2 hours, filter, filtrate recycling ethanol is concentrated in the time of 15～30 ℃ relative density and is 1.15～1.30 clear paste spray drying and gets dried powder;
(c) natural Broneolum Syntheticum is ground into fine powder,, adds in the appropriate amount of auxiliary materials with above-mentioned powder mixes, fully mix, mixture stirs at 60～85 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 60～85 ℃ of temperature following system, dropper bore is 1.21～3.5 millimeters, splashes in 0～18 ℃ the liquid paraffin, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 9
(a) get Folium Ginkgo 35g, Salvia miltiorrhiza Bge 35g, Herb Gynostemmae Pentaphylli 25g, natural Broneolum Syntheticum 6g, xylitol 22.4g, arabic gum 3.6g are standby;
(b) Folium Ginkgo is with 70% ethanol extraction secondary, each 2 hours, filter, consider liquid and reclaim ethanol, be concentrated into relative density and be 1.15～1.30 clear paste, spray drying, dried powder; Salvia miltiorrhiza Bge decocts with water three times, 2 hours for the first time; 1.5 hours for the second time, 0.5 hour for the third time, filter, merge and consider liquid, be concentrated into the clear paste of relative density 1.15～1.30, add ethanol and make that to contain alcohol amount be 80%, stirring makes precipitation, gets supernatant and reclaims ethanol, is concentrated into relative density and is 1.15～1.30 clear paste, spray drying, it is standby to get dry fine powder; Glue thigh orchid is with 75% alcohol reflux secondary, and each 2 hours, filter, filtrate recycling ethanol is concentrated in the time of 15～30 ℃ relative density and is 1.15～1.30 clear paste spray drying and gets dried powder;
(c) natural Broneolum Syntheticum is ground into fine powder,, adds in the mixture of xylitol and starch with above-mentioned powder mixes, fully mix, mixture stirs at 60～85 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 60～85 ℃ of temperature following system, dropper bore is 1.1～3.5 millimeters, splashes in 0～18 ℃ the methyl-silicone oil, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 10
(a) get Folium Ginkgo 35g, Salvia miltiorrhiza Bge 45g, Herb Gynostemmae Pentaphylli 25g, natural Broneolum Syntheticum 5g, xylitol 18.5g, starch 6.g are standby;
(b) Folium Ginkgo is with 70% ethanol extraction secondary, each 2 hours, filter, consider liquid and reclaim ethanol, be concentrated in the time of 20 ℃ relative density and be 1.20～1.25 clear paste, spray drying, dried powder; Salvia miltiorrhiza Bge decocts with water three times, 3 hours for the first time; 2 hours for the second time, 1 hour for the third time, filter, merge and consider liquid, be concentrated into the clear paste of relative density 1.20 in the time of 40 ℃, add ethanol and make that to contain alcohol amount be 75%, stirring makes precipitation, gets supernatant and reclaims ethanol, is concentrated in the time of 20 ℃ relative density and is 1.20～1.25 clear paste, spray drying, it is standby to get dry fine powder; Glue thigh orchid is with 75% alcohol reflux secondary, each 2 hours, filter, filtrate recycling ethanol is concentrated in the time of 20 ℃ relative density and is 1.20～1.25 clear paste spray drying, dried powder;
(c) natural Broneolum Syntheticum is ground into fine powder,, adds in xylitol and the starch mixture with above-mentioned powder mixes, fully mix, mixture stirs at 64 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 64 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splashes in 0 ℃ the methyl-silicone oil, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 11
(a) get Folium Ginkgo 35g, Salvia miltiorrhiza Bge 45g, Herb Gynostemmae Pentaphylli 25g, natural Broneolum Syntheticum 5g, lactose 15.5g, starch 35.g are standby;
(b) Folium Ginkgo is with 70% ethanol extraction secondary, each 2 hours, filter, consider liquid and reclaim ethanol, be concentrated in the time of 20 ℃ relative density and be 1.20～1.25 clear paste, spray drying, dried powder; Salvia miltiorrhiza Bge decocts with water three times, 3 hours for the first time; 2 hours for the second time, 1 hour for the third time, filter, merge and consider liquid, be concentrated into the clear paste of relative density 1.20 in the time of 40 ℃, add ethanol and make that to contain alcohol amount be 75%, stirring makes precipitation, gets supernatant and reclaims ethanol, is concentrated in the time of 20 ℃ relative density and is 1.20～1.25 clear paste, spray drying, it is standby to get dry fine powder; Glue thigh orchid is with 75% alcohol reflux secondary, each 2 hours, filter, filtrate recycling ethanol is concentrated in the time of 20 ℃ relative density and is 1.20～1.25 clear paste spray drying, dried powder;
(c) natural Broneolum Syntheticum is ground into fine powder,, adds in lactose and the starch mixture with above-mentioned powder mixes, fully mix, mixture stirs at 64 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 64 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splashes in 0 ℃ the methyl-silicone oil, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 12
(a) get Folium Ginkgo 35g, Salvia miltiorrhiza Bge 45g, Herb Gynostemmae Pentaphylli 25g, Blumeae preparatum Tabellae 5g, xylitol 23.8g, chitin 4.2g are standby;
(b) Folium Ginkgo is with 70% ethanol extraction secondary, each 2 hours, filter, consider liquid and reclaim ethanol, be concentrated in the time of 20 ℃ relative density and be 1.20～1.25 clear paste, spray drying, dried powder; Salvia miltiorrhiza Bge decocts with water three times, 3 hours for the first time; 2 hours for the second time, 1 hour for the third time, filter, merge and consider liquid, be concentrated into the clear paste of relative density 1.20 in the time of 40 ℃, add ethanol and make that to contain alcohol amount be 75%, stirring makes precipitation, gets supernatant and reclaims ethanol, is concentrated in the time of 20 ℃ relative density and is 1.20～1.25 clear paste, spray drying, it is standby to get dry fine powder; Glue thigh orchid is with 75% alcohol reflux secondary, each 2 hours, filter, filtrate recycling ethanol is concentrated in the time of 20 ℃ relative density and is 1.20～1.25 clear paste spray drying, dried powder;
(c) Blumeae preparatum Tabellae is ground into fine powder,, adds in the appropriate amount of auxiliary materials with above-mentioned powder mixes, fully mix, mixture stirs at 60～68 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 60～68 ℃ of temperature following system, dropper bore is 1.21～2.5 millimeters, splashes in 0 ℃ the methyl-silicone oil, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 13
Get the Folium Ginkgo that extracts by embodiment 11 methods, Salvia miltiorrhiza Bge, Herb Gynostemmae Pentaphylli extract 1g, finely divided ice 5g, xylitol 22.3g, chitin 6.7g is standby;
Said extracted thing and borneol powder are mixed, add in xylitol and the chitin mixture, fully mix, mixture is at 60～68 ℃ of heating and meltings, stir, mixing time is 10～30 minutes, and insulation is 1.21～2.5 millimeters at 60～68 ℃ of temperature following system, dropper bore, splash in 0 ℃ the methyl-silicone oil, make 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 14
Get the Folium Ginkgo that extracts by embodiment 11 methods, Salvia miltiorrhiza Bge, Herb Gynostemmae Pentaphylli extract 5g, finely divided ice 5g, xylitol 20g, starch 5g is standby;
Said extracted thing and borneol powder are mixed, add in xylitol and the starch mixture, fully mix, mixture is at 60～68 ℃ of heating and meltings, stir, mixing time is 10～30 minutes, and insulation is 1.21～2.5 millimeters at 60～68 ℃ of temperature following system, dropper bore, splash in 0 ℃ the methyl-silicone oil, make 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 15
Get the Folium Ginkgo that extracts by embodiment 11 methods, Salvia miltiorrhiza Bge, Herb Gynostemmae Pentaphylli extract 8g, finely divided ice 2g, xylitol 17.8g, arabic gum 7.2g is standby;
Said extracted thing and borneol powder are mixed, add in xylitol and the arabic gum mixture, fully mix, mixture is at 60～68 ℃ of heating and meltings, stir, mixing time is 10～30 minutes, and insulation is 1.21～2.5 millimeters at 60～68 ℃ of temperature following system, dropper bore, splash in 0 ℃ the methyl-silicone oil, make 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 16
Get the Folium Ginkgo that extracts by embodiment 11 methods, Salvia miltiorrhiza Bge, Herb Gynostemmae Pentaphylli extract 8g, finely divided ice 5g, xylitol 17.6g, starch 4.4g is standby;
Said extracted thing and borneol powder are mixed, add in xylitol and the starch mixture, fully mix, mixture is at 60～68 ℃ of heating and meltings, stir, mixing time is 10～30 minutes, and insulation is 1.21～2.5 millimeters at 60～68 ℃ of temperature following system, dropper bore, splash in 0 ℃ the methyl-silicone oil, make 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 17
Get the Folium Ginkgo that extracts by embodiment 11 methods, Salvia miltiorrhiza Bge, Herb Gynostemmae Pentaphylli extract 8g, finely divided ice 4.5g, xylitol 26.5g, chitin 8.5g is standby;
Said extracted thing and borneol powder are mixed, add in xylitol and the starch mixture, fully mix, mixture is at 60～68 ℃ of heating and meltings, stir, mixing time is 10～30 minutes, and insulation is 1.21～2.5 millimeters at 60～68 ℃ of temperature following system, dropper bore, splash in 0 ℃ the methyl-silicone oil, make 2000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 18
Get the Folium Ginkgo that extracts by embodiment 11 methods, Salvia miltiorrhiza Bge, Herb Gynostemmae Pentaphylli extract 9g, finely divided ice 1g, xylitol 31.5g, chitin 8.5g is standby:
Said extracted thing and borneol powder are mixed, add in xylitol and the starch mixture, fully mix, mixture is at 60～68 ℃ of heating and meltings, stir, mixing time is 10～30 minutes, and insulation is 1.21～2.5 millimeters at 60～68 ℃ of temperature following system, dropper bore, splash in 0 ℃ the methyl-silicone oil, make 2000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Embodiment 19
Earlier with Folium Ginkgo 35g with 70% ethanol extraction 2 times, each 2 hours, filter, filtrate recycling ethanol, the concentrated solution spray drying gets dried powder; Radix Salviae Miltiorrhizae 45g decocts with water 3 times, and the 1st time 3 hours, the 2nd time 2 hours, the 3rd time 1 hour, filter, merge 3 times filtrate, be concentrated into relative density 1.20, add ethanol again and stir and to make precipitation, get supernatant and reclaim ethanol, the concentrated solution spray drying gets dry powder: Herb Gynostemmae Pentaphylli 25g is with 75% ethanol extraction 2 times, each 2 hours, filter, filtrate recycling ethanol, the concentrated solution spray drying gets powder; Blumeae preparatum Tabellae is ground into fine powder,, adds in xylitol and the starch mixture with above-mentioned three powder mixes that make, fully mix, mixture stirs at 60～68 ℃ of heating and meltings, and mixing time is 10～30 minutes, insulation, at 60～68 ℃ of temperature following system, dropper bore is 1.21～2.5 millimeters, splashes in 0 ℃ the methyl-silicone oil, makes 1000 drop pill, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Claims (13)
1, a kind of medicine for the treatment of the thoracic obstruction, it is characterized in that it is by 18～55 parts of Folium Ginkgos, 23～68 parts of Salvia miltiorrhiza Bges, 12～36 parts of Herb Gynostemmae Pentaphylli, 2.5～7.5 parts of natural Broneolum Syntheticums, appropriate amount of auxiliary materials is made, wherein adjuvant comprises filler and plasticity substrate, said filler is selected from the natural adjuvant of following one or more plant origins: erythritol, sorbitol, fructose, D-ribonic acid-gamma lactone, arabitol, trehalose, D-ribose, low melting-point agarose, Lac, xylitol, Raffinose, glucose, malic acid, citric acid, isomalt, lactose, maltose etc., and they contain the water of crystallization chemical compound; Said plasticity substrate is selected from the natural adjuvant of following one or more plant origins: starch and derivant thereof, cellulose and derivant thereof, arabic gum, dextran, chitin, sesbania gum, carrageenan, Ficus elastica, Furcellaran, tragakanta, carrageenin, tamarind gum, pectin, xanthan gum, alginic acid and salt thereof, dextrin, cyclodextrin, agar, lactose; Described starch and derivant thereof such as pregelatinized Starch, modified starch, hydroxypropyl starch, carboxymethyl starch, described cellulose and derivant thereof such as methylcellulose, microcrystalline Cellulose, sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, cross-linking sodium carboxymethyl cellulose, hydroxyethylmethyl-cellulose, hydroxyethyl-cellulose, hydroxypropyl cellulose.
2, the medicine of the treatment thoracic obstruction as claimed in claim 1, it is characterized in that it is to be made by 30～40 parts of Folium Ginkgos, 35～55 parts of Salvia miltiorrhiza Bges, 20～30 parts of Herb Gynostemmae Pentaphylli, 4～6 parts of natural Broneolum Syntheticums, appropriate amount of auxiliary materials, filler adjuvant wherein is selected from following one or more the natural adjuvant of plant origin: sorbitol, xylitol, lactose, maltose, and they contain the water of crystallization chemical compound; Plasticity substrate wherein is selected from following one or more the natural adjuvant of plant origin: pregelatinized Starch, carboxymethyl starch, methylcellulose, sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, arabic gum, alginic acid, dextrin, cyclodextrin, agar, lactose.
3, the medicine of the treatment thoracic obstruction as claimed in claim 1 or 2, it is characterized in that it is to be made by 35 parts of Folium Ginkgos, 45 parts of Salvia miltiorrhiza Bges, 25 parts of Herb Gynostemmae Pentaphylli, 5 parts of natural Broneolum Syntheticums, appropriate amount of auxiliary materials, filler adjuvant wherein is selected from following one or more the natural adjuvant of plant origin: xylitol, lactose; Plasticity substrate wherein is selected from following one or more the natural adjuvant of plant origin: starch, arabic gum.
4, as the medicine of claim 1, the 2 or 3 described treatment thoracic obstruction, it is characterized in that it can also contain chemosynthesis adjuvant and animal origin adjuvant in above-mentioned dressing, wherein filler comprises phenylglycol, hexadecanol, octadecanol, sodium stearate, tristerin, tripalmitin, carbamide, polyoxyethylene monostearate, polyoxyethylene alkyl ether; Wherein plasticity substrate comprises polyvinylpyrrolidone, crospolyvinylpyrrolidone, carbomer, polyvinyl alcohol, acrylic resin, poloxamer, gelatin.
5, the medicine of the treatment thoracic obstruction as claimed in claim 3 is characterized in that adjuvant described in this medicine is xylitol and starch, and xylitol is 1: 0.2～1: 0.3 with the ratio of the weight of starch.
6, the medicine of the treatment thoracic obstruction as claimed in claim 3 is characterized in that adjuvant described in this medicine is lactose and starch, and lactose is 1: 0.2～1: 0.3 with the ratio of the weight of starch.
7, the medicine of the treatment thoracic obstruction as claimed in claim 3 is characterized in that adjuvant described in this medicine is xylitol and arabic gum, and the ratio of the weight of xylitol and arabic gum is 1: 0.2～1: 0.4.
8,, it is characterized in that the adjuvant and the ratio of the weight of extract drugs extractum are 1: 0.1～1: 1 as the medicine of claim 1, the 2 or 3 described treatment thoracic obstruction.
9,, it is characterized in that the adjuvant and the ratio of the weight of extract drugs extractum are 1: 0.1～1: 0.6 as the medicine of claim 1, the 2 or 3 described treatment thoracic obstruction.
10,, it is characterized in that the adjuvant and the ratio of the weight of extract drugs extractum are 1: 0.2～1: 0.4 as the medicine of claim 1, the 2 or 3 described treatment thoracic obstruction.
11, the preparation method of claim 1,2 or 3 described treatment thoracic obstruction medicines is characterized in that this method comprises the steps:
(a) it is standby to take by weighing 18～55 parts of each crude drug Folium Ginkgos, 23～68 parts of Salvia miltiorrhiza Bges, 12～36 parts of Herb Gynostemmae Pentaphylli, 2.5～7.5 parts of natural Broneolum Syntheticums by proportioning;
(b) Folium Ginkgo is with 50～90% ethanol extraction secondary, each 0.5～5 hour, filter, consider liquid and reclaim ethanol, be concentrated into relative density and be 1.05～1.35 clear paste, spray drying, dried powder; Salvia miltiorrhiza Bge decocts with water three times, 1～5 hour for the first time; 0.5～4 hour for the second time, 0.5～2 hour for the third time, filter, merge and consider liquid, be concentrated into the clear paste of relative density 1.10～1.35, add ethanol and make that to contain alcohol amount be 50～85%, stirring makes precipitation, gets supernatant and reclaims ethanol, is concentrated into relative density and is 1.10～1.35 clear paste, spray drying, it is standby to get dry fine powder; Glue thigh orchid is with 50～95% alcohol reflux secondary, and each 0.5～5 hour, filter, filtrate recycling ethanol is concentrated in the time of 10～40 ℃ relative density and is 1.05～1.35 clear paste spray drying and gets dried powder;
(c) natural Broneolum Syntheticum is ground into fine powder, with above-mentioned powder mixes, add in the appropriate amount of auxiliary materials, fully mix, mixture is at 45～115 ℃ of heating and meltings, stir, mixing time is 1～120 minute, insulation, at 45～95 ℃ of temperature following system, dropper bore is 1.0～4.0 millimeters, splash in-20～25 ℃ liquid paraffin, methyl-silicone oil or the vegetable oil, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
12, the preparation method of treatment thoracic obstruction medicine as claimed in claim 11 is characterized in that this method comprises the steps:
(a) it is standby to take by weighing 30～40 parts of each crude drug Folium Ginkgos, 35～55 parts of Salvia miltiorrhiza Bges, 20～30 parts of Herb Gynostemmae Pentaphylli, 4～6 parts of natural Broneolum Syntheticums by proportioning;
(b) Folium Ginkgo is with 60～80% ethanol extraction secondary, each 1～3 hour, filter, consider liquid and reclaim ethanol, be concentrated into relative density and be 1.15～1.30 clear paste, spray drying, dried powder; Salvia miltiorrhiza Bge decocts with water three times, 2～4 hours for the first time; 1～3 hour for the second time, 0.5～1.5 hour for the third time, filter, merge and consider liquid, be concentrated into the clear paste of relative density 1.15～1.30, add ethanol and make that to contain alcohol amount be 60～80%, stirring makes precipitation, gets supernatant and reclaims ethanol, is concentrated into relative density and is 1.15～1.30 clear paste, spray drying, it is standby to get dry fine powder; Glue thigh orchid is with 60～80% alcohol reflux secondary, and each 1～3 hour, filter, filtrate recycling ethanol is concentrated in the time of 15～30 ℃ relative density and is 1.15～1.30 clear paste spray drying and gets dried powder;
(c) natural Broneolum Syntheticum is ground into fine powder, with above-mentioned powder mixes, add in the appropriate amount of auxiliary materials, fully mix, mixture is at 60～85 ℃ of heating and meltings, stir, mixing time is 10～30 minutes, insulation, at 60～85 ℃ of temperature following system, dropper bore is 1.1～3.5 millimeters, splash in 0～18 ℃ the liquid paraffin, methyl-silicone oil, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
13, the preparation method of treatment thoracic obstruction medicine as claimed in claim 11 is characterized in that this method comprises the steps:
(a) it is standby to take by weighing 35 parts of each crude drug Folium Ginkgos, 45 parts of Salvia miltiorrhiza Bges, 25 parts of Herb Gynostemmae Pentaphylli, 5 parts of natural Broneolum Syntheticums by proportioning;
(b) Folium Ginkgo is with 70% ethanol extraction secondary, each 2 hours, filter, consider liquid and reclaim ethanol, be concentrated in the time of 20 ℃ relative density and be 1.20～1.25 clear paste, spray drying, dried powder; Salvia miltiorrhiza Bge decocts with water three times, 3 hours for the first time; 2 hours for the second time, 1 hour for the third time, filter, merge and consider liquid, be concentrated into the clear paste of relative density 1.20 in the time of 40 ℃, add ethanol and make that to contain alcohol amount be 75%, stirring makes precipitation, gets supernatant and reclaims ethanol, is concentrated in the time of 20 ℃ relative density and is 1.20～1.25 clear paste, spray drying, it is standby to get dry fine powder; Glue thigh orchid is with 75% alcohol reflux secondary, each 2 hours, filter, filtrate recycling ethanol is concentrated in the time of 20 ℃ relative density and is 1.20～1.25 clear paste spray drying, dried powder;
(c) natural Broneolum Syntheticum is ground into fine powder, with above-mentioned powder mixes, add in the appropriate amount of auxiliary materials, fully mix, mixture is at 64 ℃ of heating and meltings, stir, mixing time is 10～30 minutes, insulation, at 64 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splash in 0 ℃ the methyl-silicone oil, with the drop pill drop to the greatest extent and wipe liquid coolant, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101072916A CN100553620C (en) | 2003-12-11 | 2003-12-11 | A kind of medicine for the treatment of the thoracic obstruction |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101072916A CN100553620C (en) | 2003-12-11 | 2003-12-11 | A kind of medicine for the treatment of the thoracic obstruction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1626132A true CN1626132A (en) | 2005-06-15 |
| CN100553620C CN100553620C (en) | 2009-10-28 |
Family
ID=34758100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2003101072916A Expired - Fee Related CN100553620C (en) | 2003-12-11 | 2003-12-11 | A kind of medicine for the treatment of the thoracic obstruction |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100553620C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101015527B (en) * | 2006-02-08 | 2011-05-18 | 天津天士力制药股份有限公司 | Dropping pills preparation |
| CN105380993A (en) * | 2015-11-19 | 2016-03-09 | 哈尔滨圣吉药业股份有限公司 | Yindanxintai dispersible tablet and preparation method thereof |
-
2003
- 2003-12-11 CN CNB2003101072916A patent/CN100553620C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101015527B (en) * | 2006-02-08 | 2011-05-18 | 天津天士力制药股份有限公司 | Dropping pills preparation |
| CN105380993A (en) * | 2015-11-19 | 2016-03-09 | 哈尔滨圣吉药业股份有限公司 | Yindanxintai dispersible tablet and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100553620C (en) | 2009-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1626122A (en) | Medication for treating cardiovascular and cerebrovascular diseases | |
| CN1626141A (en) | Medication for relieving cough and asthma | |
| CN100450504C (en) | Medication for treating pharyngitis | |
| CN1626132A (en) | Medication for treating obstruction of qi in the chest | |
| CN100421684C (en) | Medication for treating coronary heart disease and angina | |
| CN1626145A (en) | Medication for treating cough | |
| CN1626126A (en) | Drop pills of healthy energy of wrinkled gianthyssop | |
| CN100553617C (en) | A kind of medicine for the treatment of obstruction of qi in the chest and cardialgia | |
| CN1626121A (en) | Preparation of Chinese traditional medicine for treating coronary heart disease and angina | |
| CN1872099A (en) | Medication for treating cardiovascular diseases, and cerebrovascular disease | |
| CN1872327A (en) | Composition of medicine for treating diarrhea | |
| CN1626134A (en) | Medication for treating chronic rhinitis and nasal sinuitis | |
| CN1626124A (en) | Drop pills of medical broth of small bupleurum root | |
| CN1872250A (en) | Composition of medication for treating headache | |
| CN1626133B (en) | Medication for treating coronary heart disease | |
| CN100512824C (en) | Medication for treating headache | |
| CN100421658C (en) | Medication for treating coronary heart disease and angina | |
| CN100421702C (en) | Medication for treating obstruction of qi in the chest | |
| CN100536831C (en) | Medication for treating cardiovascular and cerebrovascular diseases | |
| CN100553619C (en) | A kind of treatment coronary heart disease, anginal medicine | |
| CN1626138A (en) | Medication for treating coronary heart disease and angina | |
| CN1626152A (en) | Medication for treating ache | |
| CN1872111A (en) | Medication for treating cardiovascular diseases and cerebrovascular disease | |
| CN1626150A (en) | Medication for treating dysmenorhea | |
| CN100512841C (en) | Medication for treating bronchitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin science and Technology Park of Beichen Xinyi Road Liaohe Road No. 1 white Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300402 Tianjin science and Technology Park of Beichen Xinyi Road Liaohe Road No. 1 white Patentee before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin science and Technology Park of Beichen Xinyi Road Liaohe Road No. 1 white Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300402 Tianjin science and Technology Park of Beichen Xinyi Road Liaohe Road No. 1 white Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091028 Termination date: 20191211 |